NCT04003610 2025-11-04Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)Incyte CorporationPhase 2 Terminated7 enrolled 10 charts